PTC Therapeutics Inc (PTCT)
Official siteHEALTHCARE • BIOTECHNOLOGY • NASDAQ
Market Cap: $5.09B
Last updated: Nov 17, 2026 at 4:20 PM ET
PTC Therapeutics Inc (PTCT) Statistics
PTC Therapeutics (PTCT) has a market cap of $5.09B and an enterprise value of $4.63B. Revenue fell 42.84% over the last 12 months from the 12 months before. Its share count is up 6.21% from a year earlier.
Total Valuation
Enterprise value is 9.01% below the market cap, as cash exceeds debt.
| Market Cap | $5.09B |
|---|---|
| Enterprise Value | $4.63B |
| Latest price (Nov 17, 2026) | $60.36 |
Key Dates
The next earnings report is expected on Feb 17, 2027, covering the quarter ending Dec 31, 2026.
| Next Earnings Date | Feb 17, 2027 (expected) |
|---|---|
| Last Earnings Date | Oct 29, 2026 |
| Fiscal Year End | December |
Valuation Ratios
The price to sales ratio is 5.0x. Its year-end P/S ranged from 2.2x to 10.5x from 2016 to 2025.
| P/S Ratio | 5.0x |
|---|---|
| Forward P/S | 3.9x |
Enterprise Valuation
Counting debt and cash, the company is valued at 29.3x EBITDA.
| EV / Sales | 4.6x |
|---|---|
| EV / EBITDA | 29.3x |
| EV / EBIT | 39.2x |
Price Statistics
The stock is down 19.84% over 52 weeks and trades 5.36% below its 50-day average.
| Beta (1Y) | 0.86 |
|---|---|
| 52-Week Change | -19.84% |
| 1-Month Change | -1.90% |
| 3-Month Change | -18.07% |
| 6-Month Change | -14.15% |
| 5-Year Change | +58.11% |
| 10-Year Change | +865.70% |
| Total Return (1Y) | -19.84% |
| Total Return (3Y CAGR) | +43.41% |
| Total Return (5Y CAGR) | +8.90% |
| Return vs SPY (1Y) | -32.85% |
| Max Drawdown (1Y) | -33.85% |
| Max Drawdown (3Y) | -36.70% |
| Sharpe Ratio (1Y) | -0.56 |
| Correlation with SPY (1Y) | 0.28 |
| 50-Day Average | $63.78 |
| 200-Day Average | $70.02 |
| 52-Week Range | $58.80 to $90.87 |
| RSI (14 Days) | 41.5 |
| Average Volume (20 Days) | 1.07M |
The 5 and 10 year changes compare month-end closes, adjusted for splits, through Oct 2026.
Financial Position
Current assets cover 3.39x current liabilities.
| Current Ratio | 3.39x |
|---|---|
| Quick Ratio | 3.28x |
| Debt / EBITDA | 3.80x |
Returns and Efficiency
Return on invested capital is 18.05% over the last 12 months, against a 5-year average of 319.83%.
| Return on Assets (ROA) | -1.18% |
|---|---|
| Return on Invested Capital (ROIC) | 18.05% |
| Return on Capital Employed (ROCE) | 4.77% |
| ROA (5Y Average) | -18.12% |
| ROIC (5Y Average) | 319.83% |
| Asset Turnover | 0.34x |
| Inventory Turnover | 0.28x |
| Receivables Turnover | 4.40x |
| Cash Conversion Cycle | -3991 days |
Scores
PTCT has an Altman Z-Score of 0.75, in the distress zone below 1.81, and a Piotroski F-Score of 7 of 9, in the average band of 3 to 7.
Altman Z-ScoreDistress below 1.81Safe above 2.99
Piotroski F-ScoreWeak at 2 or lessStrong at 8 or more
| Altman Z-Score | 0.75 |
|---|---|
| Altman Z Zone | Distress |
| Piotroski F-Score | 7 of 9 |
| Piotroski Strength | Average |
Income Statement
Revenue was $1.01B over the last 12 months.
| Revenue | $1.01B |
|---|---|
| Revenue Growth (YoY) | -42.84% |
| Gross Profit | $985.09M |
| Operating Income | $125.60M |
| Pretax Income | -$67.07M |
| Net Income | -$38.38M |
| EBITDA | $155.40M |
| EBIT | $118.22M |
| Reported EPS (TTM) | -$0.30 |
Trailing 12 months through Jun 30, 2026.
Balance Sheet
| Cash and Equivalents | $1.05B |
|---|---|
| Total Debt | $590.97M |
| Net Cash | $458.92M |
| Net Cash Per Share | $5.53 |
| Working Capital | $1.85B |
| Shareholder Equity | -$165.36M |
| Tangible Book Value | -$650.63M |
| Total Assets | $3.25B |
| Total Liabilities | $3.42B |
Balance sheet as of Jun 30, 2026.
Cash Flow
After $9.21M of capital spending, operating cash flow left -$39.71M of free cash flow.
| Operating Cash Flow | -$30.50M |
|---|---|
| Capital Expenditures | $9.21M |
| Free Cash Flow | -$39.71M |
| FCF Per Share | -$0.48 |
| Depreciation and Amortization | $73.41M |
Trailing 12 months through Jun 30, 2026.
Margins
The operating margin is 12.45%, against a 5-year average of -33.56%.
| Gross Margin | 97.65% |
|---|---|
| Operating Margin | 12.45% |
| Pretax Margin | -6.65% |
| Net Margin | -3.80% |
| EBITDA Margin | 15.41% |
| EBIT Margin | 11.72% |
| FCF Margin | -3.94% |
| Gross Margin (5Y Average) | 96.10% |
| Operating Margin (5Y Average) | -33.56% |
| Net Margin (5Y Average) | -49.93% |
Growth
Revenue grew 35.30% a year over 3 years.
| Revenue Growth (3Y CAGR) | +35.30% |
|---|---|
| Revenue Growth (5Y CAGR) | +35.37% |
Dividends and Yields
PTCT does not pay a dividend. Its free cash flow yield is -0.79%.
| FCF Yield | -0.79% |
|---|---|
| Buyback Yield | -0.06% |
| Shareholder Yield | -0.06% |
Peer Position
Against 8 similar companies, PTCT has the lowest P/S.
P/S RatioPeer median 12.9x
ROICPeer median -23.06%
Revenue Growth (Trailing 4 Quarters, YoY)Peer median +37.67%
| P/S Ratio | 5.0x vs 12.9x median |
|---|---|
| ROIC | 18.05% vs -23.06% median |
| Revenue Growth (Trailing 4 Quarters, YoY) | -42.84% vs +37.67% median |
Analyst Forecast
Consensus estimates put revenue growth at -9.13% and EPS growth at -35.21% a year over the next 2 fiscal years.
| Revenue Growth Forecast (2Y CAGR) | -9.13% |
|---|---|
| EPS Growth Forecast (2Y CAGR) | -35.21% |
Price Target
Analyst price targets are part of paid GNG plans. See plans
GNG Valuation
| GNG view | Fairly valued |
|---|
GNG fair value is part of GNG Pro. See plans
Frequently Asked Questions About PTCT
What is PTCT's market cap?
PTC Therapeutics has a market cap of $5.09B. Its enterprise value, which adds debt and subtracts cash, is $4.63B.
How many shares of PTCT are outstanding?
PTC Therapeutics has 83.01M shares outstanding. The count is up 6.21% from a year earlier.
Does PTCT pay a dividend?
No. PTC Therapeutics does not pay a dividend.
How much debt does PTCT have?
PTC Therapeutics has $590.97M of total debt and $1.05B of cash and equivalents, a net cash position of $458.92M.
PTCT pages: Overview, Charting, Earnings, Forecast, Financials, Statistics, Valuation, Competitors